Who is the CEO of JW Pharmaceutical?

According to the DART company overview, JW Pharmaceutical's representative director is 대표이사 신영섭, 함은경(각자 대표이사) (name as registered in Korean). The company was founded on 1945-08-08.

Where is JW Pharmaceutical listed?

JW Pharmaceutical trades on the Korea Exchange KOSPI market under the ticker 001060. Its fiscal year ends in December.

Does JW Pharmaceutical pay a dividend?

Yes. For fiscal 2025, JW Pharmaceutical paid a cash dividend of ₩650 per common share, a 2.1% yield as stated in its annual report, with a payout ratio of 25.5%. The prior year's dividend was ₩450.

Does JW Pharmaceutical have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Dividend grower (dividend per share raised three years in a row); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as JW Pharmaceutical?

Under the Korean Standard Industrial Classification recorded on DART, JW Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

JW Pharmaceutical KRX:001060KOSPI

JW중외제약 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h3

Articles, 7 days7

DART filings, 7 days0

Articles tracked267since Sep 11

In Q2 2026, JW Pharmaceutical reported revenue of ₩222bn, up 16.2% year on year, and operating profit of ₩33.3bn. JW Pharmaceutical (JW중외제약) appeared in 7 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 7 articles. The most common catalyst was clinical & approvals (6). It was most often mentioned alongside HK inno.N, Hanmi Pharm and DongKookPharmaceutical.

Filing signals Revenue & profit growth Dividend grower M&A / stake deal Screener

JW Pharmaceutical quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩222bn	+16.2%	₩33.3bn margin 15.0%	₩27.9bn
Q1 2026	₩200bn	+7.9%	₩33.6bn margin 16.8%	₩27.5bn
Q4 2025 derived	₩199bn	+5.9%	₩15.5bn margin 7.8%	₩15.3bn
Q3 2025	₩200bn	+12.0%	₩32.0bn margin 16.0%	₩30.6bn
Q2 2025	₩191bn	+10.9%	₩25.0bn margin 13.1%	−₩1.9bn
Q1 2025	₩185bn	+2.6%	₩22.0bn margin 11.9%	₩17.5bn
Q4 2024 derived	₩188bn	-8.4%	₩18.1bn margin 9.6%	₩16.6bn
Q3 2024	₩179bn	-3.0%	₩26.5bn margin 14.9%	₩19.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

JW Pharmaceutical top stories 2 weeks, by number of outlets

1
JW중외제약, 비뇨의학회 학술대회서 ‘트루패스’ 심포지엄
3 outlets · 3 articlesFirst report Oct 21 11:50 메디포뉴스
2
JW중외제약 ‘엠파가드’, 임상 3상서 혈당 조절 효과 확인
2 outlets · 2 articlesFirst report Oct 29 13:32 메디컬투데이Clinical trial
3
JW중외제약, 내분비학회서 SGLT-2 기반 3제 신약 ‘엠파가드’ 3상 결과 발표
2 outlets · 2 articlesFirst report Oct 29 13:52 더바이오Clinical trial
4
JW중외제약, '트루패스' 심포지엄…고령 환자 치료 가치 조명
2 outlets · 2 articlesFirst report Oct 21 11:57 메디파나뉴스
5
[Pharma Report] JW중외제약, 당뇨병 복합제 ‘엠파가드’ 임상 3상 공개 外
1 outlets · 1 articlesFirst report Oct 29 16:28 헬스코리아뉴스Clinical trial
6
JW중외제약, 대한내분비학회서 ‘엠파가드’ 임상 3상 결과 발표
1 outlets · 1 articlesFirst report Oct 29 16:55 메드월드뉴스Clinical trial

Latest JW Pharmaceutical news Korean headlines

Oct 2916:55

MajorJW중외제약, 대한내분비학회서 ‘엠파가드’ 임상 3상 결과 발표
메드월드뉴스Clinical trial
Oct 2916:28

Major[Pharma Report] JW중외제약, 당뇨병 복합제 ‘엠파가드’ 임상 3상 공개 外
헬스코리아뉴스Clinical trial
Oct 2913:52
MajorJW중외제약, 내분비학회서 SGLT-2 기반 3제 신약 ‘엠파가드’ 3상 결과 발표
더바이오Clinical trial
1 more on this story · 1 outlets
- JW중외제약, 30일 내분비학회서 엠파가드 3상 결과 발표 예정메디포뉴스 · Oct 29 14:59
Oct 2913:32
MajorJW중외제약 ‘엠파가드’, 임상 3상서 혈당 조절 효과 확인
메디컬투데이Clinical trial
1 more on this story · 1 outlets
- JW중외제약 ‘엠파가드’, 임상 3상서 혈당 조절 효과 확인알파경제 · Oct 29 13:32
Oct 2605:37

JW중외제약, 2026 성천상 시상식 개최
청년의사
Oct 2308:59

JW중외제약 도입 자궁근종약 ‘린자골릭스’, 주사제와 효과 대등
헬스코리아뉴스
Oct 2307:00

JW중외제약 4세 이기환, 미국법인 CEO 등재…경영 참여 확대
PRESS9
Oct 2118:11

JW중외제약, 2026 대한비뇨의학회서 '트루패스' 심포지엄 성료
보건신문
Oct 2113:55

JW중외제약, 대한비뇨의학회서 ‘트루패스’ 임상 가치 조명
메디코파마
Oct 2111:57
JW중외제약, '트루패스' 심포지엄…고령 환자 치료 가치 조명
메디파나뉴스
1 more on this story · 1 outlets
- JW중외제약, 전립선비대증 치료제 ‘트루패스’ 고령 환자 임상 가치 조명메디컬투데이 · Oct 21 13:33
Oct 2111:50
JW중외제약, 비뇨의학회 학술대회서 ‘트루패스’ 심포지엄
메디포뉴스
2 more on this story · 2 outlets
- JW중외제약, 대한비뇨의학회 학술대회서 '트루패스' 심포지엄 개최더바이오 · Oct 21 11:54
- JW중외제약, 대한비뇨의학회 학술대회서 '트루패스' 심포지엄메드월드뉴스 · Oct 21 16:12
Oct 2015:14

주요 중견 제약사 합산 시총 1년 새 보합, 동국제약ㆍJW중외제약 증가
의약뉴스DongKookPharmaceutical
Oct 2003:41

JW중외제약, 일반약 PDRN 외용제 시장 가세 … 10년 독점 깨지고 ‘7파전’ 재편
헬스코리아뉴스
Oct 1908:23

한미약품 비만신약 '에페' 출시 임박…JW중외제약·HK이노엔도 국내 시장 진입 채비
메디컬투데이Hanmi Pharm HK inno.N
Oct 1517:36

'리바로'로 곳간 채운 JW중외제약… 대사질환 풀라인업 속도
아시아투데이
Oct 1513:36

"MZ 충성도 업고 영토 확장"⋯JW중외제약 '프렌즈'의 변신
아이뉴스24
Oct 1508:40

“요즘 나는솔로에 보이던데” JW중외제약, 숙취해소제 ‘가네톡톡’ 매출 잰걸음
CatchNews
Oct 1308:00

MajorJW중외제약·공정위, 299억 과징금 소송 쌍방 상고…대법원 판단 받는다
메디컬투데이Negative news
Oct 1307:56
JW중외제약, 프렌즈 새 광고 모델로 에스파 선정
메디포뉴스
1 more on this story · 1 outlets
- JW중외제약, '프렌즈 아이드롭' 새 모델로 에스파 발탁FETV · Oct 13 10:44
Oct 1306:02

JW중외제약, AI 신약 첫 상용화 도전…'에파미뉴라드' 허가 채비
메디파나뉴스
Oct 1223:30

“퍽퍽한 눈에 에스파가 찾아온다”… JW중외제약 ‘프렌즈’, 더 촉촉하게 변신
지이코노미
Oct 1218:30

JW중외제약, 에스파 출연 '프렌즈' 광고 20일 온에어… 포장도 개편
더퍼블릭
Oct 1217:51

당대 톱스타 '에스파' 내세운 JW중외제약, 30년 만 강호동도 소환
이코노미스트
Oct 1217:20

유한양행 JW중외제약 外(제약보국)
뉴스클레임Yuhan
Oct 1215:55

JW중외제약, 에스파 앞세워 프렌즈 아이케어 광고 전개
라이센스뉴스
Oct 1213:50

JW중외제약, '프렌즈X에스파'..."눈길은 끌고 눈가는 맑게"
메트로신문
Oct 1211:06
JW중외제약, 인공눈물 모델로 가수 ‘에스파’ 선정
조선비즈
3 more on this story · 3 outlets
- JW중외제약, 인공눈물 모델로 가수 ‘에스파’ 선정조선일보 · Oct 12 11:11
- [영상]JW중외제약, '프렌즈 아이드롭' 새 모델로 에스파 선정비즈니스플러스 · Oct 12 13:56
- JW중외제약, 프렌즈 아이드롭 새 모델로 에스파 선정한국면세뉴스 · Oct 12 17:19
Oct 1209:58
JW중외제약, '프렌즈' 모델 에스파 발탁…인공눈물 패키지도 새단장
PRESS9
1 more on this story · 1 outlets
- JW중외제약, 인공눈물 ‘프렌즈’ 모델로 그룹 에스파 발탁스페셜타임스 · Oct 12 19:11
Oct 1209:42

[위클리오늘] 산업일반 소식_JW중외제약, 대원제약, GC케어(10,12)
위클리오늘Daewon Pharmaceutical
Oct 1209:21

JW중외제약, 공정위와 '쌍방 상고'…대법원서 최종 법리 다툼
EBN

Articles per day 2 weeks

119

220

721

223

126

629

Company profile

CEO: 대표이사 신영섭, 함은경(각자 대표이사)
Industry: Pharmaceuticals
Founded: 1945-08-08
Fiscal year-end: December
Head office: 경기도 과천시
Website: jw-pharma.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

JW Pharmaceutical dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩650	2.1%	25.5%
FY2024	₩450	1.9%	17.0%
FY2023	₩400	1.1%	25.1%

Raised 3 years in a row

JW Pharmaceutical in the market close daily wrap

All wraps

Samsung, LG Electronics, HLB Lead Busy Korea News DayTue, Oct 6

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

JW홀딩스45.89%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
HK inno.N	₩30.0bn	183

Compare JW Pharmaceutical side by side with these companies

JW Pharmaceutical DART filings

Oct 816:19

Other [기재정정]벌금등의부과
Other
Sep 2916:33

Equity acquisition / disposal 타법인주식및출자증권취득결정
Contracts & investment
Sep 1817:28

Other [기재정정]벌금등의부과
Other
Sep 1710:15

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 1710:00

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 1709:55

Other 최대주주등소유주식변동신고서
Other

Catalysts 2 weeks

Clinical & approvals6

Mentioned alongside 2 weeks

JW Pharmaceutical FAQ

Who is the CEO of JW Pharmaceutical?: According to the DART company overview, JW Pharmaceutical's representative director is 대표이사 신영섭, 함은경(각자 대표이사) (name as registered in Korean). The company was founded on 1945-08-08.
Where is JW Pharmaceutical listed?: JW Pharmaceutical trades on the Korea Exchange KOSPI market under the ticker 001060. Its fiscal year ends in December.
What were JW Pharmaceutical's latest quarterly results?: In Q2 2026, JW Pharmaceutical reported revenue of ₩222bn, up 16.2% year on year, and operating profit of ₩33.3bn. Figures come from reports filed on DART.
Does JW Pharmaceutical pay a dividend?: Yes. For fiscal 2025, JW Pharmaceutical paid a cash dividend of ₩650 per common share, a 2.1% yield as stated in its annual report, with a payout ratio of 25.5%. The prior year's dividend was ₩450.
Does JW Pharmaceutical have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Dividend grower (dividend per share raised three years in a row); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as JW Pharmaceutical?: Under the Korean Standard Industrial Classification recorded on DART, JW Pharmaceutical is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.